Search results for "Progression"

showing 10 items of 1251 documents

Functional Metagenomics of the Bronchial Microbiome in COPD

2015

Altres ajuts: Sociedad Catalana de Neumología; Fundació Catalana de Neumología; Fundació Parc Tauli; Marató de TV3; Sociedad Española de Neumología y Cirugía Torácica; Fundación Menarini; Generalitat Valenciana (Spain) [Prometeo/2009/092] i Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES) The course of chronic obstructive pulmonary disease (COPD) is frequently aggravated by exacerbations, and changes in the composition and activity of the microbiome may be implicated in their appearance. The aim of this study was to analyse the composition and the gene content of the microbial community in bronchial secretions of COPD patients in both stability and exacerbati…

MaleExacerbationlcsh:MedicineCarbohydrate metabolismBiologyBioinformaticsPulmonary Disease Chronic ObstructiveRNA Ribosomal 16SmedicineHumansMicrobiomeKEGGlcsh:ScienceLungAgedCOPDMultidisciplinaryLungBacteriaMicrobiotaChronic obstructive pulmonary diseaselcsh:RSputumMiddle Agedmedicine.diseasemedicine.anatomical_structureRibosomal RNAMetagenomicsImmunologyDisease ProgressionMetagenomeSputumPyrosequencingFemalelcsh:QMicrobiomeSequence databasesMetagenomicsmedicine.symptomResearch ArticlePLOS ONE
researchProduct

Regional anticoagulation with heparin of an extracorporeal CO2 removal circuit: a case report

2019

Abstract Background Extracorporeal carbon dioxide removal is an increasingly used respiratory support technique. As is true of all extracorporeal techniques, extracorporeal carbon dioxide removal needs proper anticoagulation. We report a case of a patient at risk of bleeding complications who was treated with extracorporeal carbon dioxide removal and anticoagulated with a regional technique. Case presentation A 56-year-old Caucasian man with a history of chronic obstructive pulmonary disease exacerbation required extracorporeal carbon dioxide removal for severe hypercapnia and acidosis despite mechanical ventilation. The extracorporeal circuit was anticoagulated using a regional heparin tec…

MaleExtracorporeal CirculationLow platelet countExacerbationmedicine.medical_treatment2lcsh:MedicineCase Report030204 cardiovascular system & hematologyExtracorporealExtracorporeal carbon dioxide removal03 medical and health sciencesContinuous venovenous filtrationPulmonary Disease Chronic Obstructive0302 clinical medicineExtracorporeal CO 2 removalExtracorporeal Membrane OxygenationmedicineHeparin regional anticoagulationHumansAcidosisMechanical ventilationbusiness.industryHeparinMedicine (all)removallcsh:RAnticoagulantsExtracorporeal COGeneral MedicineHeparinExtracorporeal CO2 removalCarbon DioxideMiddle AgedRespiration ArtificialTreatment Outcome030220 oncology & carcinogenesisAnesthesiaDisease Progressionmedicine.symptomContinuous venovenous filtration; Extracorporeal CO ; 2; removal ; Heparin regional anticoagulationbusinessHypercapniamedicine.drugJournal of Medical Case Reports
researchProduct

Follistatin as potential therapeutic target in prostate cancer

2012

Follistatin is a single-chain glycosylated protein whose primary function consists in binding and neutralizing some members of the transforming growth factor-β superfamily such as activin and bone morphogenic proteins. Emerging evidence indicates that this molecule may also play a role in the malignant progression of several human tumors including prostate cancer. In particular, recent findings suggest that, in this tumor, follistatin may also contribute to the formation of bone metastasis through multiple mechanisms, some of which are not related to its specific activin or bone morphogenic proteins' inhibitory activity. This review provides insight into the most recent advances in understa…

MaleFollistatinendocrine systemCancer Researchmedicine.medical_specialtyanimal structuresGlycosylated proteinProstate cancerInternal medicinemedicineAnimalsHumansPharmacology (medical)Molecular Targeted TherapyActivin Bone metastasis.Cancer . Follistatin Prostate cancerbiologybusiness.industryProstatic NeoplasmsCancerBone metastasisSUPERFAMILYmedicine.diseaseEndocrinologyOncologyembryonic structuresDisease Progressionbiology.proteinCancer researchbusinesshormones hormone substitutes and hormone antagonistsFunction (biology)FollistatinTransforming growth factor
researchProduct

Cancer cells induce immune escape via glycocalyx changes controlled by the telomeric protein TRF2

2019

International audience; Myeloid-derived suppressor cells (MDSCs) are immature myeloid cells with strong immunosuppressive activity that promote tumor growth. In this study, we describe a mechanism by which cancer cells control MDSCs in human cancers by upregulating TRF2, a protein required for telomere stability. Specifically, we showed that the TRF2 upregulation in cancer cells has extratelomeric roles in activating the expression of a network of genes involved in the biosynthesis of heparan sulfate proteoglycan, leading to profound changes in glycocalyx length and stiffness, as revealed by atomic force microscopy. This TRF2-dependent regulation facilitated the recruitment of MDSCs, their …

MaleHSPG;immunosurveillance;MDSC;NK cells;TRF2Mice NudeBiologyGlycocalyxGeneral Biochemistry Genetics and Molecular BiologyMetastasisGlycocalyx03 medical and health sciencesMice0302 clinical medicineDownregulation and upregulationNeoplasmsmedicineAnimalsHumansTelomeric Repeat Binding Protein 2STAT3Molecular BiologyCells Cultured030304 developmental biology0303 health sciencesGeneral Immunology and MicrobiologyGeneral NeuroscienceMyeloid-Derived Suppressor CellsArticlesTelomeremedicine.disease3. Good healthImmunosurveillanceGene Expression Regulation NeoplasticMice Inbred C57BLTLR2HEK293 CellsTumor progressionCancer cellCancer researchbiology.proteinNIH 3T3 Cells[SDV.IMM]Life Sciences [q-bio]/ImmunologyFemaleTumor Escape030217 neurology & neurosurgery
researchProduct

Non-invasive markers of airway inflammation and remodeling in childhood asthma

2009

To evaluate the relationship between pro-inflammatory and pro-remodeling mediators and severity and control of asthma in children, the levels of IL-8, MMP-9, TIMP-1 in induced sputum supernatants, the number of sputum eosinophils, as well as FeNO, were investigated in 35 asthmatic children, 12 with intermittent (IA) and 23 with moderate asthma (MA), and 9 controls (C). The patients with asthma were followed for 1 yr and sputum was obtained twice during the follow-up. Biomarker levels were correlated with the number of exacerbations. We found that IL-8, MMP-9, TIMP-1 and the numbers of eosinophils in induced sputum, as well as FeNO, were increased in children with IA and MA in comparison to …

MaleHumans; Disease Progression; Asthma; Child; Leukocyte Count; Eosinophils; Bronchitis; Follow-Up Studies; Sputum; Interleukin-8; Adolescent; Tissue Inhibitor of Metalloproteinase-1; Matrix Metalloproteinase 9; Biological Markers; Female; MaleAdolescentImmunologyInflammationDiseaseEosinophilBronchitiFollow-Up StudieLeukocyte CountImmunology and AllergyMedicineHumansNONINVASIVE MARKERS INFLAMMATION REMODELING CHILDHOOD ASTHMAProspective cohort studyBronchitisChildAsthmaChildhood asthmaTissue Inhibitor of Metalloproteinase-1business.industryInterleukin-8Airway inflammationSputumrespiratory systemmedicine.diseaseAsthmarespiratory tract diseasesEosinophilsMatrix Metalloproteinase 9Pediatrics Perinatology and Child HealthImmunologyBiological MarkerDisease ProgressionSputumBiomarker (medicine)Femalemedicine.symptombusinessBiomarkersHumanFollow-Up Studies
researchProduct

The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics

2020

Abstract Background The Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD; NCT03036150) trial was designed to assess the effect of the sodium–glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin on kidney and cardiovascular events in participants with CKD with and without type 2 diabetes (T2D). This analysis reports the baseline characteristics of those recruited, comparing them with those enrolled in other trials. Methods In DAPA-CKD, 4304 participants with a urinary albumin:creatinine ratio (UACR) ≥200 mg/g and estimated glomerular filtration rate (eGFR) between 25 and 75 mL/min/1.73 m2 were randomized to dapagliflozin 10 mg once daily or placebo. Me…

MaleIGA NEPHROPATHYRATIONALEPROGRESSIONType 2 diabetesurologic and male genital diseasesDiabetic nephropathychemistry.chemical_compoundGlucosidesDESIGNMedicineFAILUREDiabetic NephropathiesDapagliflozinrandomized controlled clinical trialPrognosisfemale genital diseases and pregnancy complications//purl.org/pe-repo/ocde/ford#3.02.13 [https]Cardiovascular DiseasesNephrologyFemalesodium–glucose co-transporter-2 inhibitormedicine.symptomBENAZEPRILGlomerular Filtration Ratemedicine.medical_specialtyFinerenoneINHIBITIONNephropathy//purl.org/pe-repo/ocde/ford#3.02.20 [https]Double-Blind MethodClinical ResearchInternal medicineDiabetes mellitusEND-POINTSHumansBenzhydryl CompoundsRenal Insufficiency ChronicAcademicSubjects/MED00340Sodium-Glucose Transporter 2 InhibitorsAgedTransplantationDECLINEbusiness.industrysodium-glucose co-transporter-2 inhibitordapagliflozinmedicine.diseaseEFFICACYEditor's ChoiceDiabetes Mellitus Type 2chemistryAlbuminuriaORIGINAL ARTICLESbusinesschronic kidney diseaseKidney disease
researchProduct

Association of Osteoarthritis with Increased Risk of Cardiovascular Diseases in the Elderly: Findings from the Progetto Veneto Anziano Study Cohort

2015

Objective The possible relevance of osteoarthritis (OA) as a cardiovascular disease (CVD) risk factor is still debated. The aim of this study was to investigate the association between OA and the onset of CVD in older individuals. Methods Among a sample of 3,099 elderly subjects, 2,158 were identified as having no CVD at baseline and were followed up for a mean ± SD 4.4 ± 1.2 years. OA was defined using a standardized algorithm that investigated disease history, medical documentation (including radiographic reports), symptoms, and physical examination of the joints. Incident CVD was defined as the onset of coronary artery disease, heart failure, stroke/transient ischemic attack, peripheral …

MaleIMPACTImmunologyUNITED-STATESPROGRESSIONCoronary Artery DiseaseKNEE OSTEOARTHRITISNOCohort StudiesPeripheral Arterial DiseaseRheumatologyImmunology; Immunology and Allergy; RheumatologyRisk FactorsOsteoarthritisEPIDEMIOLOGYHumansImmunology and AllergyObesityAgedDyslipidemiasProportional Hazards ModelsAged 80 and overHeart FailureDISABILITYMORTALITYIncidencePREVALENCEHospitalizationLipoproteins LDLStrokeATHEROSCLEROSISItalyCardiovascular DiseasesIschemic Attack TransientHypertensionFemaleARTHRITISFollow-Up Studies
researchProduct

Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice.

2018

It is judged safe to discontinue treatment with tyrosine kinase inhibitors (TKI) for chronic myeloid leukemia (CML) in experimental trials on treatment-free remission (TFR). We collected a total of 293 Italian patients with chronic phase CML who discontinued TKI in deep molecular response. Seventy-two percent of patients were on treatment with imatinib, and 28% with second generation TKI at the time of discontinuation. Median duration of treatment with the last TKI was 77 months [Interquartile Range (IQR) 54;111], median duration of deep molecular response was 46 months (IQR 31;74). Duration of treatment with TKI and duration of deep molecular response were shorter with second generation TK…

MaleImatinib mesylate discontinuation; chronic myelogenous leukemia; treatment-free remission; long-term outcomes; molecular response; cml patients; recommendations; management; dasatinib; cessationchemistry.chemical_compound0302 clinical medicineTreatment Free RemissionPregnancyMED/15 - MALATTIE DEL SANGUEInterquartile rangeingleseMedicinedasatinibChronic Myelogenous Leukemiatreatment-free remissionPonatinibmolecular responseHematologyMiddle AgedProtein-Tyrosine Kinasescml patientsDasatinibTreatment OutcomeLeukemia Myeloid Chronic-PhaseDisease ProgressionImatinib MesylateFemaleChronic Myelogenous Leukemia; Discontinuation; Treatment Free Remissionlong-term outcomesmanagementmedicine.drugAdultmedicine.medical_specialtyChronic Myeloid LeukemiaSocio-culturaleDiscontinuationArticletyrosine kinase inhibitors discontinued treatment chronic myeloid leukemia treatment-free remission (TFR)Safety-Based Drug Withdrawals03 medical and health scienceschronic myeloid leukemia tyrosine kinase inhibitors discontinuationMedian follow-upLeukemia Myelogenous Chronic BCR-ABL PositiveInternal medicineImatinib mesylate discontinuationHumansProtein Kinase InhibitorsRetrospective Studiesbusiness.industryImatinibmedicine.diseaseDiscontinuationrespiratory tract diseasesSettore MED/15 - MALATTIE DEL SANGUEcessationNilotinibchemistryrecommendationsbusiness030215 immunologyChronic myelogenous leukemia
researchProduct

Infantile hemangiomas with minimal or arrested growth: A retrospective case series

2018

Background/objectives Infantile hemangiomas (IH) with minimal or arrested growth (MAG) constitute a distinctive subset of IH based on their clinical characteristics and natural history. They are often confused with capillary malformations. Methods A retrospective observational study has been carried out in which clinical and perinatal characteristics have been evaluated in all IH-MAG evaluated in our Dermatology Department in a 5-year period (January 2013-December 2017). Results A total of 14 IH-MAG affecting 13 patients were identified (10 girls and 3 boys). All were born full term, with a mean birth weight of 3448 g for girls vs 3540 g for boys, corresponding to the 72nd percentile for bo…

MaleInvolution (mathematics)Pediatricsmedicine.medical_specialtySkin NeoplasmsBirth weightAdrenergic beta-AntagonistsDermatologyPropranololHemangioma030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicinemedicineHumansChildRetrospective StudiesHigh birth weightFull Termbusiness.industryInfantRetrospective cohort studymedicine.diseasePropranololNatural historyChild Preschool030220 oncology & carcinogenesisPediatrics Perinatology and Child HealthDisease ProgressionFemaleHemangiomabusinessmedicine.drugPediatric Dermatology
researchProduct

Enhanced glomerular Toll-like receptor 4 expression and signaling in patients with type 2 diabetic nephropathy and microalbuminuria

2014

Toll-like receptor 4 (TLR4), a component of the innate immune system, is recognized to promote tubulointerstitial inflammation in overt diabetic nephropathy (DN). However, there is no information on immune activation in resident renal cells at an early stage of human DN. In order to investigate this, we studied TLR4 gene and protein expression and TLR4 downward signaling in kidney biopsies of 12 patients with type 2 diabetes and microalbuminuria, and compared them with 11 patients with overt DN, 10 with minimal change disease (MCD), and control kidneys from 13 patients undergoing surgery for a small renal mass. Both in microalbuminuria and in overt DN, TLR4 mRNA and protein were overexpress…

MaleKidney GlomerulusDiabetic nephropathyurologic and male genital diseasesDiabetic nephropathynefropatiadiabeticaDiabetic NephropathiesMinimal change diseaseChemokine CCL5KidneyMiddle AgedUp-RegulationKidney Tubulesmedicine.anatomical_structureNephrologyDisease ProgressionFemaleHumanSignal Transductionmedicine.medical_specialtyReceptors CCR5Receptors CCR2NephrosisAntigens Differentiation MyelomonocyticFollow-Up StudieNephropathyToll-like receptorAntigens CDDiabetes mellitusInternal medicinemedicineAlbuminuriaHumansRNA MessengerInflammationInterleukin-6Tumor Necrosis Factor-alphabusiness.industryNephrosis LipoidKidney TubuleTranscription Factor RelABiomarkermedicine.diseaseImmunity InnateToll-Like Receptor 4EndocrinologyDiabetes Mellitus Type 2Diabetic NephropathieTLR4MicroalbuminuriaKidney GlomerulubusinessBiomarkersMicroalbuminuriaFollow-Up StudiesKidney International
researchProduct